大剂量阿托伐他汀对经皮冠状动脉介入治疗患者术后造影剂肾病的影响(2)
综上所述,大剂量阿托伐他汀能通过减轻全身炎症反应,减轻造影剂的肾功能损害,从而降低CIN的发生率。也许大剂量阿托伐他汀会是CIN预防措施中的又一选择,但本研究尚可能受样本量及患者其他某些混杂因素影响,仍需大样本量多中心研究进一步明确。
[参考文献]
[1] Cavusoglu E,Chhabra S,Marmur JD,et al.The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention[J].Minerva Cardioangiol,2004,52(5):419-432.
[2] Horl WH.Contrast induced nephropathy[J].Wien Klin Woch-enschr,2009,121(1-2):15-32.
[3] 高润霖.他汀类药物在急性冠脉综合征的应用[J].中华心血管病杂志,2003,31(8):635-636.
[4] Peter A,Pierre A.Nephrotoxic effects in high-risk patients undergoing angiography[J].N Engl J Med,2003,348(6):491-499.
[5] Marenzi G,Lauri G,Assanelli E,et al.Contrast-induced nephropathy in patients undergoing primary angiophasty for acute myocardial infarction[J].Am Coll Cardiol,2004,44(9):1780-1785.
[6] 胡大一,马长生.心脏病学实践[M].北京:人民卫生出版社,2005:218,425.
[7] Solomon R,Mehran R,Natarajan M,et al.Contrast-induced nephropathy and long-term adverse events:cause and effect?[J].Clin J Am Soc Nephrol,2009,4(7):1162-1169.
[8] 周霞,金元哲,王琦,等.大剂量阿托伐他汀预防对比剂肾病[J].中华心血管病杂志,2009,37(5):394-396.
[9] Attallah N,Yassine L,Musial J,et al.The potential role of statins in contrast nephropathy[J].Clin Nephrol,2004,62(4):273-278.
[10] Ozhan H,Erden I,Ordu S,et al.Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J].Angiology,2010,61(7):711-714.
[11] Patti G,Nusca A,Chello M,et al.Usefuless of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention[J].Am J Cardiol,2008,101(3):279-285.
[12] 童保文,林志鸿,谢良地,等.兔颈动脉球囊损伤后血小板聚集和活化及阿托伐他汀的作用[J].南方医科大学学报,2014,34(8):1162-1166.
[13] 刘继东,崔连群,刘尊齐,等.阿托伐他汀快速降低老年不稳定性心绞痛患者血清炎症因子浓度[J].中华心血管病杂志,2006,34(10):942.
[14] 陈光铃,苏津自.阿托伐他汀改善对比剂对肾功能的短期影响[J].中华心血管病杂志,2009,37(5):389-393.
[15] Jia XW,Fu XH,Zhang J,et al.Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].Am J Cardiol,2009,104(4):519-524.
(收稿日期:2014-09-24 本文编辑:李亚聪) (黄钒)
[参考文献]
[1] Cavusoglu E,Chhabra S,Marmur JD,et al.The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention[J].Minerva Cardioangiol,2004,52(5):419-432.
[2] Horl WH.Contrast induced nephropathy[J].Wien Klin Woch-enschr,2009,121(1-2):15-32.
[3] 高润霖.他汀类药物在急性冠脉综合征的应用[J].中华心血管病杂志,2003,31(8):635-636.
[4] Peter A,Pierre A.Nephrotoxic effects in high-risk patients undergoing angiography[J].N Engl J Med,2003,348(6):491-499.
[5] Marenzi G,Lauri G,Assanelli E,et al.Contrast-induced nephropathy in patients undergoing primary angiophasty for acute myocardial infarction[J].Am Coll Cardiol,2004,44(9):1780-1785.
[6] 胡大一,马长生.心脏病学实践[M].北京:人民卫生出版社,2005:218,425.
[7] Solomon R,Mehran R,Natarajan M,et al.Contrast-induced nephropathy and long-term adverse events:cause and effect?[J].Clin J Am Soc Nephrol,2009,4(7):1162-1169.
[8] 周霞,金元哲,王琦,等.大剂量阿托伐他汀预防对比剂肾病[J].中华心血管病杂志,2009,37(5):394-396.
[9] Attallah N,Yassine L,Musial J,et al.The potential role of statins in contrast nephropathy[J].Clin Nephrol,2004,62(4):273-278.
[10] Ozhan H,Erden I,Ordu S,et al.Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J].Angiology,2010,61(7):711-714.
[11] Patti G,Nusca A,Chello M,et al.Usefuless of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention[J].Am J Cardiol,2008,101(3):279-285.
[12] 童保文,林志鸿,谢良地,等.兔颈动脉球囊损伤后血小板聚集和活化及阿托伐他汀的作用[J].南方医科大学学报,2014,34(8):1162-1166.
[13] 刘继东,崔连群,刘尊齐,等.阿托伐他汀快速降低老年不稳定性心绞痛患者血清炎症因子浓度[J].中华心血管病杂志,2006,34(10):942.
[14] 陈光铃,苏津自.阿托伐他汀改善对比剂对肾功能的短期影响[J].中华心血管病杂志,2009,37(5):389-393.
[15] Jia XW,Fu XH,Zhang J,et al.Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].Am J Cardiol,2009,104(4):519-524.
(收稿日期:2014-09-24 本文编辑:李亚聪) (黄钒)